tbuckley/cabot-search huggingface dataset:
Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health
Authors: Alan F. List, Zhuoxin Sun, Amit Verma, John M. Bennett, Kathy McGraw, Jaroslaw P. Maciejewski, Rami S. Komrokji, Timothy R. Wassenaar, Selina M. Luger, Ryan J. Mattison, Puneet S. Cheema, Jessica K. Altman, David F. Claxton, Charles A. Schiffer, Andrew S. Artz, Mark Litzow, Martin S. Tallman
Journal: Blood (2019)
Response to Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. Diabetes Care 2019;42:1088–1094
Authors: Sascha Pilemann-Lyberg, Tine Willum Hansen, Peter Rossing
Journal: Diabetes Care (2019)

We appreciate the comments by Chen et al. (1) regarding our investigation of the association between serum uric acid (UA) and the risk of developing complications in patients with type 1 diabetes (2). We found that increased levels of UA, expressed as hazard ratio per doubling of UA, was a significant and independent risk factor for loss of renal function, cardiovascular events, and mortality. However, in a previous study investigating UA in the same cohort with shorter follow-up time and no data on hard end points, we were not able to show any association between UA and loss of …
OUTCOMES OF PATIENTS INTERRUPTING GLECAPREVIR/PIBRENTASVIR TREATMENT: A CASE SERIES FROM CLINICAL TRIALS
Authors: Philippe Zamor, John Dillon, Douglas Dylla, David J. Mutimer, Reem Ghalib, Massimo Colombo, Richard Skoien, Eric D. Crown, Yiran Hu, Eric J. Lawitz
Journal: Hepatology (2019)
Autism spectrum disorder and attention deficit hyperactivity disorder have a similar burden of rare protein-truncating variants
Authors: F. Kyle Satterstrom, Raymond K. Walters, Tarjinder Singh, Emilie M. Wigdor, Francesco Lescai, Ditte Demontis, Jack A. Kosmicki, Jakob Grove, Christine Stevens, Jonas Bybjerg-Grauholm, Marie Bækvad-Hansen, Duncan S. Palmer, Julian B. Maller, Merete Nordentoft, Ole Mors, Elise B. Robinson, David M. Hougaard, Thomas M. Werge, Preben Bo Mortensen, Benjamin M. Neale, Anders D. Børglum, Mark J. Daly
Journal: Nature Neuroscience (2019)
Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment
Authors: Aurélie Caye, Kevin Rouault-Pierre, Marion Strullu, Elodie Lainey, Ander Abarrategi, Odile Fenneteau, Chloé Arfeuille, Jennifer Osman, Bruno Cassinat, Sabrina Pereira, Fernando Anjos-Afonso, Erin Currie, Linda Ariza-McNaughton, Vincent Barlogis, Jean-Hugues Dalle, André Baruchel, Christine Chomienne, Hélène Cavé, Dominique Bonnet
Journal: Leukemia (2019)

Abstract Juvenile myelomonocytic leukemia (JMML) is a rare aggressive myelodysplastic/myeloproliferative neoplasm of early childhood, initiated by RAS-activating mutations. Genomic analyses have recently described JMML mutational landscape; however, the nature of JMML-propagating cells (JMML-PCs) and the clonal architecture of the disease remained until now elusive. Combining genomic (exome, RNA-seq), Colony forming assay and xenograft studies, we detect the presence of JMML-PCs that faithfully reproduce JMML features including the complex/nonlinear organization of dominant/minor clones, both at diagnosis and relapse. Further integrated analysis also reveals that although the mutations are acquired in hematopoietic stem cells, JMML-PCs are not always restricted to this compartment, highlighting the heterogeneity of the disease during the initiation steps. We show that the hematopoietic stem/progenitor cell phenotype is globally maintained in JMML despite overexpression of CD90/THY-1 in a subset of patients. This study shed new lights into the ontogeny of JMML, and the identity of JMML-PCs, and provides robust models to monitor the disease and test novel therapeutic approaches.
Erratum: Corrigendum: Inter-individual variability and genetic influences on cytokine responses to bacteria and fungi
Authors: Yang Li, Marije Oosting, Patrick Deelen, Isis Ricaño-Ponce, Sanne Smeekens, Martin Jaeger, Vasiliki Matzaraki, Morris A Swertz, Ramnik J Xavier, Lude Franke, Cisca Wijmenga, Leo A B Joosten, Vinod Kumar, Mihai G Netea
Journal: Nature Medicine (2016)
Ablation therapy in atrial fibrillation
Authors: Alysha Bhatti, Pippa Oakeshott, Mehul Dhinoja, Julia Grapsa
Journal: BMJ (2019)

### What you need to know

Atrial fibrillation has a prevalence of 1% in the general population and 6% in those aged over 60 years. It increases the risk of stroke fivefold and doubles the risk of death.1 Although it is often asymptomatic, symptoms may include palpitations, breathlessness, dizziness, and exercise intolerance and lead to a reduced quality of life.2

Atrial fibrillation can be managed with pharmacotherapy, but ablation therapy (catheter ablation) is an option for symptomatic patients who wish to avoid or cannot tolerate medication. Once a cardiologist has assessed that the patient is a suitable candidate for the procedure, patients may have further questions to put to their general practitioner or other care provider. To aid these discussions, this practice pointer outlines what ablation therapy entails, the potential risks, the likelihood of success, and postoperative advice.

The number of catheter ablation procedures carried out for atrial fibrillation has risen, with over 6000 procedures being performed annually in the UK (approximately 100/million population).3 The National Institute for Health and Care Excellence (NICE) recommends the use of percutaneous radiofrequency ablation for those whose atrial fibrillation is causing symptoms and who have not responded to, or wish to avoid, anti-arrhythmic medication or in whom such medication is contraindicated.4

### Normalising arrythmia

In …
REPLY:
Authors: Fredrik Åberg, Martti Färkkilä, Veikko Salomaa, Antti Jula
Journal: Hepatology (2019)

Potential conflict of interest: Dr. Salomaa consults for Sanofi, advises Novo Nordisk, and received grants from Bayer. The other authors have nothing to report. We thank doctors Gow, Testro, Hey, and Sinclair for their interest in our study and for sharing their views on the potential benefits of alcohol. Indeed, we found an association between light alcohol use and reduced all‐cause mortality and reduced incidence of cardiovascular disease (CVD) in never smokers with nonalcoholic fatty liver disease (NAFLD).1 However, this observation does not necessarily translate into a benefit of alcohol as a therapeutic approach in CVD prevention, mainly because of potential residual confounding from, for instance, an imbalance in dietary patterns between light drinkers and abstainers. The J‐shaped association between alcohol and mortality observed in several population studies was recently challenged by the Global Burden of Disease (GBD) study2 and by a large Asian Mendelian randomization study analyzing genetic proxies for drinking habits.3 Controversy also exists in NAFLD regarding the effect of alcohol on CVD risk.4 One of the methodological issues introduced by the GBD investigators to better overcome difficult‐to‐control bias from residual confounding and reverse causation was the exclusion of all abstainers. In our study, we excluded former drinkers but not lifetime abstainers. When reanalyzed in our population NAFLD cohort after the additional exclusion of lifetime abstainers, similar to the GBD study, the apparent mortality–benefit of light alcohol use diminishes (Fig. 1).Figure 1: The relationship between daily alcohol consumption and risk for incident advanced liver disease when either including or excluding lifetime alcohol abstainers, by multivariate Cox regression analysis adjusted for age, sex, marital status, education, employment, smoking, exercise, body mass index, waist circumference, diabetes, systolic blood pressure, acetylsalicylic acid use, serum glutamyltransferase, history of cancer, and history of CVD. Former drinkers (abstainers at baseline) are excluded in both analyses.Gow et al. also argue that wine could be beneficial for the liver in NAFLD. Although we found wine possibly less harmful than other alcoholic beverages at moderate‐level consumption, no liver‐protective effect was observed in our study or in the only published randomized controlled trial to date,5 in which light red wine consumption, compared with abstinence, tended to increase liver fat content rather than protect from it. Additional concerns with alcohol as a therapeutic approach include a substantial individual variation as to when alcohol starts to become harmful, probably dependent on sex, drinking pattern, genetics, obesity, and the gut microbiome. The debate over the risk–benefit of light alcohol use remains open, awaiting further prospective long‐term studies with objective measurements of cumulative alcohol consumption. In the meantime, caution with the cabernet consumption, and keep the cork closed in cirrhosis!
Cortico-Limbic Interactions Mediate Adaptive and Maladaptive Responses Relevant to Psychopathology
Authors: Rothem Kovner, Jonathan A. Oler, Ned H. Kalin
Journal: American Journal of Psychiatry (2019)

Cortico-limbic circuits provide a substrate for adaptive behavioral and emotional responses. However, dysfunction of these circuits can result in maladaptive responses that are associated with psychopathology. The prefrontal-limbic pathways are of particular interest because they facilitate interactions among emotion, cognition, and decision-making functions, all of which are affected in psychiatric disorders. Regulatory aspects of the prefrontal cortex (PFC) are especially relevant to human psychopathology, as the PFC, in addition to its functions, is more recent from an evolutionary perspective and is considerably more complex in human and nonhuman primates compared with other species. This review provides a neuroanatomical and functional perspective of selected regions of the limbic system, the medial temporal lobe structures-the hippocampus and amygdala as well as regions of the PFC. Beyond the specific brain regions, emphasis is placed on the structure and function of critical PFC-limbic circuits, linking alterations in the processing of information across these pathways to the pathophysiology and psychopathology of various psychiatric illnesses.
The Metabolic Interplay between Cancer and Other Diseases
Authors: Anne Le, Sunag Udupa, Cissy Zhang
Journal: Trends in cancer (2019)

Over the past decade, knowledge of cancer metabolism has expanded exponentially and has provided several clinically relevant targets for cancer therapy. Although these current approaches have shown promise, there are very few studies showing how seemingly unrelated metabolic processes in other diseases can readily occur in cancer. Moreover, the striking metabolic overlap between cancer and other diseases such as diabetes, cardiovascular, neurological, obesity, and aging has provided key therapeutic strategies that have even begun to be translated into clinical trials. These promising results necessitate consideration of the interconnected metabolic network while studying the metabolism of cancer. This review article discusses how cancer metabolism is intertwined with systemic metabolism and how knowledge from other diseases can help to broaden therapeutic opportunities for cancer.
Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)
Authors: D. Aziz, C. Lee, V. Chin, K. Fernandez, D. Etemadmoghadam, D. Bowtell, P.M. Waring, C.E. Caldon
Journal: Annals of Oncology (2019)
Upregulation of the Chemokine Receptor CCR4 in Cutaneous T-Cell Lymphoma and Nodal T-Cell Lymphoma: Implications for Targeted Therapy.
Authors: Dan Jones, Kaushali Patel, Marco Herling, Richard J. Aguilar, Ryuzo Ueda, Hiroshi Inagaki, Luis Fayad, Madeleine Duvic
Journal: Blood (2004)
The Importance of Sleep Phenotypes in Bipolar Disorders
Authors: David T. Plante
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
Authors: Suguru Yamada, Tsutomu Fujii, Nao Takano, Hideki Takami, Masaya Suenaga, Yukiko Niwa, Masamichi Hayashi, Naoki Iwata, Mitsuro Kanda, Daisuke Kobayashi, Chie Tanaka, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera
Journal: Journal of Clinical Oncology (2018)

523 Background: Gemcitabine plus nab-paclitaxel (GnP) treatment is recommended for metastatic pancreatic adenocarcinoma (PDAC), and has been widely spread in our clinics. However, the usefulness for the patients with locally advanced PDAC is still controversial. We designed the phase I study to assess the toxicity and decide the recommended dose based on dose-limiting toxicity (DLT) of concurrent chemoradiotherapy using GnP for unresectable locally advanced (UR-LA) PDAC. Methods: UR-LA PDAC patients were enrolled in this clinical trial. The patients received the GnP on days 1, 8 and 15 every 28 days, and the cycles were repeated until PD. The patients were scheduled to receive gemcitabine (mg/m 2 ) and nab-paclitaxel (mg/m 2 ) at 5 dose levels: 400/75 (level 0), 600/75 (level 1), 600/100 (level 2), 800/100 (level 3) and 800/125 (level 4). Radiation therapy was delivered as a total dose of 50.4 Gy in 28 fractions, 1.8Gy per day. DLT was defined as grade 4 leucopenia or neutropenia ≥ 3 days, grade 3 neutropenia with fever ≥ 38℃, grade 3 or 4 thrombopenia, grade 3 non-hematological toxicity and &gt; 14 days delay of treatment. Response and disease control rate, safety, adverse events, PFS and OS were evaluated. Results: Twelve patients were enrolled in this study. Treatment was well tolerated, and every 12 patients completed radiotherapy of 50.4 Gy. Our recommended dose was level 3, gemcitabine 800 mg/m 2 and nab-paclitaxel 100 mg/m 2 . One patient experienced the DLT. The response rate was 41.7% and disease control rate was 75% (PR: 5, SD: 4, PD: 3). Median OS was 9.0 months. Among 12 patients, 6 (50%) patients underwent conversion surgery, and the pathological CR was observed in 2 patients. Conclusions: The concurrent chemoradiotherapy using GnP for UR-LA PDAC can be delivered safely and the high rate of conversion surgery was observed in our clinical trial. Based on this results, we will proceed the phase-II study. Clinical trial information: UMIN000020475.
Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study
Authors: Gary E. Raskob, Alex C. Spyropoulos, Alexander T Cohen, Jeffrey I. Weitz, Walter Ageno, Yoriko De Sanctis, Wentao Lu, Jianfeng Xu, John Albanese, Chiara Sugarmann, Concetta Lipardi, Theodore E. Spiro, Elliot S. Barnathan
Journal: Blood (2019)
Retroperitoneal Liposarcoma on 99mTc-DTPA Renal Scintigraphy
Authors: Haotian Chen, Jing Wei, Rang Wang, Yongzhao Xiang, Chengzhong Fan
Journal: Clinical Nuclear Medicine (2019)

Retroperitoneal liposarcoma is usually large and can press on other organs. We report a case of a 66-year-old woman with a history of retroperitoneal liposarcoma resection who presented to the emergency department with abdominal pain. Ultrasonography revealed a large abdominal mass with renal displacement. Dynamic renal scintigraphy with Tc-DTPA was conducted to evaluate renal function. However, severe impairment of the right kidney function and abnormal tracer accumulation were observed during the examination. SPECT/CT was performed; 2 kidneys were successfully localized, and the recurrence of tumor was correctly detected.
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
Authors: Houssein Safa, Daniel H Johnson, Van Anh Trinh, Theresa E Rodgers, Heather Lin, Maria E Suarez-Almazor, Faisal Fa’ak, Chantal Saberian, Cassian Yee, Michael A Davies, Sudhakar Tummala, Karin Woodman, Noha Abdel-Wahab, Adi Diab
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Myasthenia gravis (MG) is a rare but life-threatening adverse event of immune checkpoint inhibitors (ICI). Given the limited evidence, data from a large cohort of patients is needed to aid in recognition and management of this fatal complication. <h3>Methods</h3> We reviewed our institutional databases to identify patients who had cancer and MG in the setting of ICI. We systematically reviewed the literature through August 2018 to identify all similar reported patients. We collected data on clinical and diagnostic features, management, and outcomes of these cases. <h3>Results</h3> Sixty-five patients were identified. Median age was 73 years; 42 (65%) were males, 31 (48%) had metastatic melanoma, and 13 (20%) had a preexisting MG before ICI initiation. Most patients received anti-PD-1 (82%). Sixty-three patients (97%) developed ICI-related MG (new onset or disease flare) after a median of 4 weeks (1 to 16 weeks) of ICI initiation. Twenty-four patients (37%) experienced concurrent myositis, and respiratory failure occurred in 29 (45%). ICI was discontinued in 61 patients (97%). Death was reported in 24 patients (38%); 15 (23%) due to MG complication. A better outcome was observed in patients who received intravenous immunoglobulin (IVIG) or plasmapheresis (PLEX) as first-line therapy than in those who received steroids alone (95% vs 63% improvement of MG symptoms, <i>p = 0.011)</i>. <h3>Conclusions</h3> MG is a life-threatening adverse event of acute onset and rapid progression after ICI initiation. Early use of IVIG or PLEX, regardless of initial symptoms severity, may lead to better outcomes than steroids alone. Our data suggest the need to reassess the current recommendations for management of ICI-related MG until prospective longitudinal studies are conducted to establish the ideal management approach for these patients.
Describing the pediatric resident experience in caring for dying patients.
Authors: Puja J. Umaretiya, Arielle Spellun, Angela Marie Feraco
Journal: Journal of Clinical Oncology (2019)

51 Background: Cancer remains the leading cause of childhood death beyond infancy. Though growing subspecialty palliative care provides expertise in caring for dying children, all pediatricians encounter dying patients and should feel adequately prepared to participate in their care. Clinicians who feel insufficiently trained in communication or end-of-life care are more likely to distance themselves from seriously ill patients and report higher levels of distress and burnout. Pediatric residents are often responsible for the frontline care of dying children in the hospital and yet, most pediatric residencies lack a formal end-of-life curriculum. Here, we aim to understand the experience of pediatric residents caring for dying patients. Methods: A thirty-four item survey instrument was administered to residents in a large pediatric residency program at a tertiary care center at Rising Junior Orientation and Rising Senior Orientation in spring 2018. All residents present completed the survey. Results: Seventy-six residents completed surveys including 46 rising juniors and 30 rising seniors. Only 19 residents (25%) reported receiving any training in caring for dying children; most of which was by noon/morning conferences or informal teaching. Nearly all (70/74; 95%) residents felt that their training in caring for dying children was not sufficient. A majority of residents reported minimal to no comfort with discussion of goals of care (73%) or resuscitation status (69%), managing pain (76%), anxiety (79%), and dyspnea (80%) at the end-of-life, performing a death exam (81%), and reaching out to families after the death of a child (85%). A majority of residents anticipate continuing to care for dying children after residency (50/76; 66%). Conclusions: Pediatric residents are uncomfortable with caring for dying patients and receive minimal training, suggesting that end-of-life care is a large gap in the pediatric residency training experience.
Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs
Authors: Genmin Lu, Joyce P. Lin, Khanh Bui, John T. Curnutte, Pamela B. Conley
Journal: Blood (2019)
Paradigm shift in esophageal diverticulum treatment: is the peroral endoscopic myotomy (POEM) technique the best method?
Authors: Hiroki Sato
Journal: Endoscopy (2019)

In the treatment of esophageal diverticula, surgical resection has traditionally been considered the only curative option. However, we are currently experiencing a paradigm shift from surgical excision to minimally invasive endoscopic treatment methods. An esophageal diverticulum itself is not malignant and the esophageal anatomy presents several challenges to open surgery, particularly when the diverticulum is near the oral orifice. Hence, the direct transoral diverticulectomy method (rigid or flexible endoscopic technique) was developed [1]; the primary purpose of these interventions being to alleviate the patients' symptoms, so we do not have to focus singularly on achieving complete excision of the diverticulum. Furthermore, based on the current issue of Endoscopy, the submucosal tunneling technique using peroral endoscopic myotomy (POEM), originally developed for achalasia [2], seems to have emerged as a mainstream treatment for esophageal diverticula beyond the previously developed direct endoscopic diverticulectomy.
Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis
Authors: Despina Moshous, Coralie Briand, Martin Castelle, Laurent Dupic, Guillaume Morelle, Wadih Abou Chahla, Vincent Barlogis, Yves Bertrand, Bénédicte Bruno, Eric Jeziorski, Catherine Paillard, Pierre Simon Rohrlich, Jean Louis Stephan, Caroline Thomas, Stéphanie Chhun, Isabelle Pellier, Aude Marie-Cardine, Mathieu Fusaro, Genevieve de Saint Basile, Capucine Picard, Caroline Elie, Benedicte Neven, Stephane Blanche, Alain Fischer
Journal: Blood (2019)
Effectiveness of the GoActive intervention to increase physical activity in adolescents aged 13–14 years: a cluster randomised controlled trial
Authors: Kirsten Corder, Stephen J Sharp, Campbell Foubister, Helen E Brown, Stephanie T Jong, Emma K Wells, Sofie Armitage, Caroline H D Croxson, Paul O Wilkinson, Edward C F Wilson, Anna Vignoles, Esther M F van Sluijs
Journal: The Lancet (2019)